title: Introduction to the application of QbD principles for the development of monoclonal antibodies.
abstract: Quality by Design (QbD) is a global regulatory initiative with the goal of enhancing pharmaceutical development through the proactive design of pharmaceutical manufacturing process and controls to consistently deliver the intended performance of the product. The principles of pharmaceutical development relevant to QbD are described in the ICH guidance documents (ICHQ8-11). An integrated set of risk assessments and their related elements developed at Roche/Genentech were designed to provide an overview of product and process knowledge for the production of a recombinant monoclonal antibody. This chapter introduces a publication series on the application of Quality by Design for biopharmaceuticals, with a focus on the development of recombinant monoclonal antibodies. The development of and overview on the QbD concept applied by Roche and Genentech is described and essential QbD elements are presented.
authors.affiliation: F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: christof.finkler@roche.com.
authors.forename: Christof
authors.initials: C
authors.lastname: Finkler
authors.affiliation: Genentech, 1 DNA Way, South San Francisco, CA, USA.
authors.forename: Lynne
authors.initials: L
authors.lastname: Krummen
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D011786:Quality Control; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins
keywords: Quality by Design